ArticleThe Journal of experimental medicine2008
Crippling HIV one mutation at a time.
Article in The Journal of experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era.Frontiers in immunology · 2022Review
- Article
- Modelling andVirus evolution · 2019Article
- Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes.Virology · 2019Article
- Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.Journal of virology · 2018Article
- Article
- Role of HIV-specific CD8The Journal of experimental medicine · 2017Article
- Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic.Journal of virology · 2016Observational
- HIV-1 vaccine immunogen design strategies.Virology journal · 2015Review
- Article
- Impaired Nef function is associated with early control of HIV-1 viremia.Journal of virology · 2014Article
- The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing.PLoS computational biology · 2014Article
- Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.Journal of virology · 2013Article
- Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness.Journal of virology · 2012Article
- Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development.Advances in virology · 2012Article
- Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.Journal of virology · 2011Article
- Immune-mediated attenuation of HIV-1.Future virology · 2011Article
- The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate.PLoS pathogens · 2011Article
- Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.Journal of virology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating data suggest that not all human immunodeficiency virus (HIV)-1-specific immune responses are equally effective at controlling HIV-1 replication. A new study now demonstrates that multiple immune-driven sequence polymorphisms in the highly conserved HIV-1 Gag region of transmitted viruses are associated with reduced viral replication in newly infected humans. These data suggest that targeting these and other conserved viral regions may be the key to developing an effective HIV-1 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.